SG160197A1 - Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist - Google Patents

Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist

Info

Publication number
SG160197A1
SG160197A1 SG200606154-3A SG2006061543A SG160197A1 SG 160197 A1 SG160197 A1 SG 160197A1 SG 2006061543 A SG2006061543 A SG 2006061543A SG 160197 A1 SG160197 A1 SG 160197A1
Authority
SG
Singapore
Prior art keywords
pde3
pde4
inhibitor
histamine receptor
pharmaceutical composition
Prior art date
Application number
SG200606154-3A
Other languages
English (en)
Inventor
Rolf Beume
Daniela Bundschuh
Christian Weimar
Stefan-Lutz Wollin
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of SG160197A1 publication Critical patent/SG160197A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG200606154-3A 2002-03-06 2003-02-25 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist SG160197A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02004987 2002-03-06

Publications (1)

Publication Number Publication Date
SG160197A1 true SG160197A1 (en) 2010-04-29

Family

ID=27771841

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200606154-3A SG160197A1 (en) 2002-03-06 2003-02-25 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist

Country Status (31)

Country Link
US (1) US20050112069A1 (enExample)
EP (2) EP1849468B1 (enExample)
JP (1) JP5150034B2 (enExample)
KR (1) KR20040095255A (enExample)
CN (1) CN101257904A (enExample)
AR (1) AR038858A1 (enExample)
AT (1) ATE369134T1 (enExample)
AU (1) AU2003212268B2 (enExample)
BR (1) BR0308220A (enExample)
CA (1) CA2478612C (enExample)
CO (1) CO5611148A2 (enExample)
CY (2) CY1106927T1 (enExample)
DE (1) DE60315426T2 (enExample)
DK (2) DK1482938T3 (enExample)
EA (2) EA010886B1 (enExample)
ES (2) ES2400670T3 (enExample)
HR (1) HRP20040909B1 (enExample)
IL (1) IL163336A (enExample)
IS (2) IS2536B (enExample)
MX (1) MXPA04008460A (enExample)
NO (1) NO335254B1 (enExample)
NZ (1) NZ535611A (enExample)
PL (1) PL211574B1 (enExample)
PT (2) PT1482938E (enExample)
RS (1) RS51018B (enExample)
SG (1) SG160197A1 (enExample)
SI (2) SI1849468T1 (enExample)
TW (1) TWI347845B (enExample)
UA (1) UA80117C2 (enExample)
WO (1) WO2003074055A1 (enExample)
ZA (1) ZA200407104B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067433B2 (en) * 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
WO2008074803A2 (en) * 2006-12-20 2008-06-26 Glaxo Group Limited 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
CA2682730A1 (en) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Use of an inhibitor of tnf.alpha. plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
WO2009067597A1 (en) * 2007-11-21 2009-05-28 Decode Genetics Ehf 4- (or 5-) substituted catechol derivatives
KR20090061972A (ko) * 2007-12-12 2009-06-17 한미약품 주식회사 베포타스틴 p-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물
RS55624B1 (sr) 2011-02-07 2017-06-30 Scipharm Sàrl Nova kompozicija za lečenje cistične fibroze
KR102226833B1 (ko) * 2013-06-28 2021-03-12 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형
CN106604747A (zh) * 2014-08-26 2017-04-26 基础应用医学研究基金会 用于治疗和预防伴随认知缺陷或缺损的神经障碍以及神经变性疾病的产品
NZ731344A (en) 2014-10-09 2018-08-31 Guangdong Raynovent Biotech Co Ltd Hydroxyl purine compounds and applications thereof
CN109956947A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 一种cns抑制剂的新晶型、制备方法及用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1005865A1 (en) * 1998-11-10 2000-06-07 Panacea Biotec Limited A anti-allergy anti-inflammatory composition comprising nimesulide and cetirizine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
CZ290266B6 (cs) * 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
AU781137B2 (en) * 1999-10-25 2005-05-05 Altana Pharma Ag Tetrahydrothiopy ranphthalazinone derivatives as PDE4 inhibitors
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1005865A1 (en) * 1998-11-10 2000-06-07 Panacea Biotec Limited A anti-allergy anti-inflammatory composition comprising nimesulide and cetirizine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A DOUBLE-BLIND, RANDOMIZED, SIN *
ANTI- INFLAMMATORY AND IMMUNOMODULATORY POTENTIAL OF THE NOVEL PDE4 INHIBITOR ROFLUMILAST IN VITRO *
EFFICACY AND SAFETY OF LEVOCETIRIZINE IN SEASONAL ALLERGIC RHINITIS *

Also Published As

Publication number Publication date
SI1482938T1 (sl) 2007-12-31
RS78004A (sr) 2006-12-15
DK1482938T3 (da) 2007-12-03
AU2003212268A1 (en) 2003-09-16
EP1482938B1 (en) 2007-08-08
EA200401137A1 (ru) 2005-04-28
ATE369134T1 (de) 2007-08-15
EP1849468B1 (en) 2012-12-05
PT1849468E (pt) 2013-02-27
EA007903B1 (ru) 2007-02-27
HK1071308A1 (en) 2005-07-15
EP1482938A1 (en) 2004-12-08
CA2478612A1 (en) 2003-09-12
IS2536B (is) 2009-08-15
WO2003074055A1 (en) 2003-09-12
SI1849468T1 (sl) 2013-03-29
ES2400670T3 (es) 2013-04-11
DE60315426T2 (de) 2008-07-03
JP5150034B2 (ja) 2013-02-20
AU2003212268B2 (en) 2008-09-11
CO5611148A2 (es) 2006-02-28
ES2291618T3 (es) 2008-03-01
UA80117C2 (uk) 2007-08-27
AR038858A1 (es) 2005-01-26
PT1482938E (pt) 2007-11-15
CY1113894T1 (el) 2016-07-27
CN101257904A (zh) 2008-09-03
EA200601592A1 (ru) 2006-12-29
EP1849468A2 (en) 2007-10-31
JP2005524666A (ja) 2005-08-18
IS8760A (is) 2008-09-04
HRP20040909A2 (en) 2005-08-31
US20050112069A1 (en) 2005-05-26
HRP20040909B1 (en) 2012-11-30
NZ535611A (en) 2006-03-31
NO335254B1 (no) 2014-10-27
DE60315426D1 (de) 2007-09-20
EA010886B1 (ru) 2008-12-30
DK1849468T3 (da) 2013-02-04
CA2478612C (en) 2013-12-10
PL371056A1 (en) 2005-06-13
KR20040095255A (ko) 2004-11-12
BR0308220A (pt) 2005-01-04
MXPA04008460A (es) 2004-12-06
RS51018B (sr) 2010-10-31
IS7438A (is) 2004-09-03
CY1106927T1 (el) 2012-09-26
IL163336A (en) 2009-02-11
NO20044230L (no) 2004-12-06
TW200306855A (en) 2003-12-01
TWI347845B (en) 2011-09-01
EP1849468A3 (en) 2007-11-07
PL211574B1 (pl) 2012-05-31
ZA200407104B (en) 2006-12-27

Similar Documents

Publication Publication Date Title
CY1106927T1 (el) Φαρμακευτικη συνθεση ενος pde4 ή pde3/4 αναστολεα και ανταγωνιστη υποδοχεα ισταμινης
HUP0302955A3 (en) Hmg-coa reductase inhibitors, pharmaceutical compositions containing them and their use for treatment of cholesterol related diseases
PL372925A1 (en) Prevention and treatment of restenosis by local administration of drug
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
GB0128108D0 (en) Therapeutic use
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
TNSN05265A1 (en) Composition comprising a pde4 inhibitor and a pde5 inhibitor
ZA200303037B (en) Herbal pharmaceutical composition for treatment of HIV/Aids patients.
MXPA03010761A (es) Combinaciones farmaceuticas.
CY1106365T1 (el) Συνδυασμος ενος αναστολεα pde και ενος ανταγωνιστη υποδοχεων λευκοτριενιου
WO2003039539A3 (de) Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
AU2002259147A1 (en) Use of neurokinin receptor antagonists to treat androgen-dependent diseases
BR0000486A (pt) Antagonistas do neuropeptìdeo y
PL369736A1 (en) New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
WO2002069944A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und nk1-rezeptor-antagonisten
AU2002254930A1 (en) Novel medicament compositions based on anticholinergic agents and endothelin antagonists
EA200100876A2 (ru) Фармацевтическая композиция для предупреждения или лечения заболевания, связанного с избыточным продуцированием il-12
WO2004002399A3 (en) Use of gaba-c receptor antagonists for the treatment of myopia
AU2002333221A1 (en) Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
HU0105291D0 (en) Pharmaceutical compositions for the treatment of indigestion and related diseases
HK1064930A (en) Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases